Insider filing · IMVT
Peter Salzmann
Chief Executive Officer
profile →
Immunovant, Inc.
IMVT · Healthcare · 33 filings in 24 months
ticker →
Peter Salzmann sold $322K of Immunovant (IMVT)
Executed Feb 19 2025, disclosed Feb 21 2025, 2 days later.
Value, as filed
$322K
15,439 sh × $20.86
Executed
Feb 19 2025
the trade date, as filed
Disclosed
Feb 21 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
PSPeter Salzmann (Chief Executive Officer) filed 6 Form 4 reports in the past 24 months (0 purchases, 6 sales), most often in Immunovant, Inc. (IMVT). The largest single filing was $425K of IMVT (16,692 sh × $25.45, as filed), executed Nov 20 2024.
The name
IMVTHealthcare · Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Peter Salzmann in IMVT
IMVTSALE
Immunovant, Inc.
$124K8,321 sh × $14.89
Exec Apr 16 2025
Filed Apr 17 2025 · 5:30 PM ET IMVTSALE Immunovant, Inc. $365K
28,094 sh × $12.99
Exec Apr 9 2025
Filed Apr 11 2025 · 5:30 PM ET IMVTSALE Immunovant, Inc. $199K
8,352 sh × $23.81
Exec Jan 15 2025
Filed Jan 17 2025 · 5:30 PM ET IMVTSALE Immunovant, Inc. $123K
5,105 sh × $24.10
Exec Jan 8 2025
Filed Jan 10 2025 · 5:30 PM ET IMVTSALE Immunovant, Inc. $425K
16,692 sh × $25.45
Exec Nov 20 2024
Filed Nov 22 2024 · 5:30 PM ET